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What is the current scientific knowledge on this subject? 
Conclusive data regarding the importance of TRPV1 as a treatment target in chronic cough has been 
lacking due the absence of a safe, potent and efficacious tool compound for use in clinical studies. In a 
previous study, a TRPV1 antagonist (SB-705498) failed to improve spontaneous cough frequency in 
treatment resistant chronic cough patients but the reduction in capsaicin-evoked cough was only 
small. 
What does this study add to the field? 
This study rules out TRPV1 as an effective therapeutic target in refractory chronic cough patients. It 
also highlights the importance of pharmacodynamic pre-clinical and clinical models in the 
interpretation of negative clinical trial data, but questions the use of cough challenge models in target 
identification. 
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ABSTRACT 
RATIONALE: Heightened cough responses to inhaled capsaicin, a TRPV1 agonist, are characteristic of 
patients with chronic cough. However, previously a TRPV1 antagonist (SB-705498) failed to improve 
spontaneous cough frequency in these patients despite small reductions in capsaicin-evoked cough.  
OBJECTIVES: XEN-D0501 (potent TRPV1 antagonist) was compared with SB-705498 in pre-clinical 
studies to establish whether an improved efficacy profile would support a further clinical trial of XEN-
D0501 in refractory chronic cough.  
METHODS: XEN-D0501 and SB-705498 were profiled against capsaicin in a sensory nerve activation 
assay and in vivo potency established against capsaicin-induced cough in the guinea pig. 
Twenty patients with refractory chronic cough participated in a double-blind, randomised, placebo-
controlled, crossover study evaluating the effect of 14 days XEN-D0501 (oral, 4mg bd) versus placebo 
on awake cough frequency (primary outcome), capsaicin-evoked cough and patient reported 
outcomes.  
MEASUREMENTS AND MAIN RESULTS: XEN-D0501 was more efficacious and 1000-fold more potent 
than SB-705498 at inhibiting capsaicin-induced depolarization of guinea pig and human isolated 
vagus. In vivo, XEN-D0501 completely inhibited capsaicin-induced cough whereas 100-times more SB-
705498 was required to achieve the same effect. In patients, XEN-D0501 substantially reduced 
maximal cough responses to capsaicin (mean change from baseline XEN-D0501 -19.3(±16.4) coughs 
vs. placebo -1.8(±5.8), p<0.0001), but not spontaneous awake cough frequency (mean change from 
baseline XEN-D0501 6.7c/h(±16.9) vs. placebo 0.4c/h(±13.7), p =0.41). 
CONCLUSIONS: XEN-D0501 demonstrated superior efficacy and potency in pre-clinical and clinical 
capsaicin challenge studies; despite this improved pharmacodynamic profile, spontaneous cough 
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frequency did not improve, ruling out TRPV1 as an effective therapeutic target for refractory cough. 
(250 words) 
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INTRODUCTION 
Chronic cough (>8 weeks duration) is thought to affect approximately 12% of the population(1). 
Patients presenting with isolated chronic cough (with normal chest radiography and spirometry) 
frequently report that coughing is associated sensations of throat irritation and an urge-to-cough, 
which are triggered by trivial exposures to environmental irritant chemicals, temperature changes and 
use of their voice(2,3). These clinical features are suggestive of a hyper-excitability of the neuronal 
pathways responsible for controlling cough. Consistent with this hypothesis, heightened cough 
responses to inhaled irritants, most commonly capsaicin, have been shown to be a characteristic 
feature in such patients(4-6). 
The cough reflex is regulated by vagal afferent nerves which innervate the airway. Some are more 
mechanically sensitive, and some are more chemosensitive; C fibres and Aδ nociceptors(7). Ion 
channels present on these vagal nerve termini can be activated by a wide variety of stimuli to elicit 
cough. The main family of ion channels implicated in the initiation of sensory reflexes are transient 
receptor potential (TRP) channels(7). Transient receptor potential vanilloid 1 (TRPV1) is a polymodal 
ion channel and was the first to be identified. It is activated by diverse stimuli including the direct 
activators capsaicin (constituent of chilli peppers from piquant Capsicum spp. Plants), noxious heat 
>42
o
C and acidic conditions/protons which interact directly with the channel to cause a lowering of its 
voltage dependency, leading to opening of the pore domain(8). It can also be activated indirectly by 
endogenous “disease relevant” mediators including bradykinin and PGE2(9,10). 
Capsaicin reliably activates the cough reflex in several species including humans, and is a specific 
TRPV1 agonist(10-13); TRPV1 is expressed by vagal afferent C- and Aδ nociceptive fibres innervating 
the airways(7). Capsaicin is the most frequently used agent for experimentally inducing cough in pre-
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clinical and clinical studies, where the concentration of capsaicin evoking at least five coughs (C5) is 
the traditional endpoint. Numerous studies have demonstrated lower capsaicin C5 in chronic cough 
compared with healthy controls (i.e. the cough reflex is more sensitive), suggesting TRPV1 could be an 
important treatment target(4,5). However, from clinical cough challenges, it cannot be determined 
whether this lowering of the cough threshold is related to changes in TRPV1 at the sensory nerve 
terminals or in central pathways. 
Only one previous clinical study has evaluated the anti-tussive effects of a single dose of a TRPV1 
antagonist (SB-705498) in patients with refractory chronic cough(12). However, disappointingly there 
was no effect on spontaneous cough frequency although there was a small but statistically significant 
impact on the capsaicin C5 (increased by approximately one doubling dose over placebo), giving some 
evidence of target engagement. These data therefore questioned the role of TRPV1 mediated 
mechanisms in patients with refractory chronic cough, however it remained unclear whether more 
potent antagonists and/or more prolonged dosing might still be efficacious. XEN-0501 is a potent and 
safe TRPV1 antagonist. It has demonstrated sub-nanomolar potency for TRPV1 receptors in human 
and rat recombinant cell systems and rat cultured dorsal root ganglia neurons and its selectivity has 
been confirmed against panels of enzymes, ion channels and G-protein coupled receptors(14). Thus 
the aims of this study were firstly to compare a potent TRPV1 antagonist (XEN-D0501) with SB-705498 
in pre-clinical studies to establish whether an improved efficacy profile would support a further 
clinical trial. Secondly, to evaluate the anti-tussive effect of XEN-D0501 in a double blind randomised 
controlled trial in patients with refractory chronic cough. Some of the results of these studies have 
been previously reported in the form of abstracts (15). 
METHODS 
For detailed methods see Online Repository. 
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PRE-CLINICAL STUDIES 
Animals 
In vivo and ex vivo experiments were conducted in male Dunkin-Hartley guinea pigs (300-500g) 
(Harlan and B&K Universal, UK). The experiments were performed in accordance with the UK Home 
Office guidelines for animal welfare based on the Animals (Scientific Procedures) act 1986 and the 
ARRIVE guidelines(16). 
Guinea-pig and human isolated vagus nerve recording 
Recording of depolarisation (as a measure of vagal, afferent sensory nerve activity) of isolated guinea-
pig and human vagus was carried out as described previously(9,17,18). Briefly, nerves were 
stimulated twice with capsaicin (1µM) for 2min before vehicle or XEN-D0501 (0.1-100nM) or SB-
705498 (1-10µM) was perfused for 10min. Response to capsaicin (1µM) was then re-assessed in 
presence of vehicle or test compounds. After a 10min washout, nerves were finally stimulated again 
with capsaicin (1µM) to confirm viability.  
Human en bloc lungs unsuitable for transplantation were obtained from International Institute for the 
Advancement of Medicine (New Jersey, USA), and vagal tissue was obtained (N=4, 36-57 years old, 3 
male).  In all cases tissue was consented for use in scientific research. Ethics approval was obtained 
from the Royal Brompton & Harefield Trust. 
Capsaicin evoked cough in guinea-pigs 
Vehicle (0.5% methylcellulose, 0.1% Tween80, 5ml/kg, i.p.) or XEN-D0501 (1-10mg/kg, i.p.) or SB-
705498 (10-100mg/kg, i.p.) were administered 1 hour prior to cough recording. Conscious, 
unrestrained guinea-pigs were placed in individual plastic transparent whole-body plethysmograph 
chambers (Buxco, Wilmington, NC, USA) and cough assessed to an aerosol of capsaicin (60µM in 1% 
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ethanol, 1% Tween 80 in 0.9% sterile saline for 5mins) and coughs counted for 10mins as previously 
described(9, 18). Studies were also performed to establish if the XEN-D0501 compound retained 
efficacy after repeat dosing. In these studies guinea-pigs were dosed with vehicle (0.5% 
methylcellulose, 0.1% Tween80, 5ml/kg, i.p.) or compound (1 or 3mg/kg, bd) for 13 days and then 1 
hour prior to cough assessment. Capsaicin-induced cough was then assessed as previously. 
CLINICAL STUDY 
Study Design 
A double-blind, randomised, placebo-controlled, crossover study was performed to evaluate the anti-
tussive efficacy of 14 days treatment with XEN-D0501 (oral 4mg bd) compared with matched placebo; 
the two treatment periods were separated by a 14 day washout, Figure 1A. Participants were 
recruited from two specialist cough clinics (University Hospital of South Manchester, Manchester and 
Belfast City Hospital, Belfast) between July 2014 and June 2015. Cough was assessed prior to dosing 
and at the end of each treatment period using an ambulatory cough monitor and patient reported 
outcomes. Capsaicin evoked cough responses were included as a pharmacodynamic endpoint. 
Participants 
We recruited subjects with refractory chronic cough, as determined by national cough guidelines (BTS 
Thorax 2006(19). An awake cough frequency of >1.5c/h and a maximal capsaicin cough response over 
4 inhalations (Emax) of >10 coughs were required for inclusion, to avoid patients with very low cough 
frequency/capsaicin-evoked cough responses, where a treatment effect would be difficult to 
demonstrate. Current smokers and ex-smokers with a smoking history of >20 pack years were 
ineligible, as were women of child-bearing potential and those taking treatments that may modulate 
cough (e.g. morphine, gabapentin). The study was approved by an independent Research Ethics 
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Committee (NRES Committee North West - Liverpool East Ref: 14/NW/0211) and all patients gave 
written informed consent. 
Study Treatment, Randomisation and Masking 
Patients were assigned to one of the two possible treatment sequences by a computer-generated 
randomisation schedule with a ratio of 1:1 for XEN-D0501/placebo or placebo/XEN-D0501. Patients, 
health-care providers, investigators and the sponsor were all masked to the treatment sequence 
assignment. The dose of XEN-D0501 used in this study (4mg bid) was considered to be the maximum 
tolerable dose in the older age group of patients typically presenting with chronic cough. 
Procedures 
Patient demographics, treatments and co-morbidities were collected at screening. Cough was 
assessed at four time points; for both treatment periods this was prior to dosing and at the end of the 
treatment period, Figure 1A. Safety was assessed through monitoring of vital signs, ECGs, body 
temperature, haematology, biochemistry and adverse events. 
Outcomes 
The primary endpoint was awake objective cough frequency collected using a 24h ambulatory cough 
monitor commenced at day 0 and day 13 of each treatment period; sleep and 24h cough frequency 
were also determined. The secondary endpoints included changes from baseline in a 100mm cough 
severity visual analogue scale (VAS), cough specific quality of life questionnaire, and also a 15-point 
global rating of change scale for cough severity and frequency, completed at the end of each 
treatment period. Cough responses to inhaled capsaicin provided a pharmacodynamic endpoint and 
were assessed on day 1 and 14, following completion of each 24h cough recording. 
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Ambulatory Cough Monitoring: Twenty-four hour acoustic recordings were made using the 
VitaloJAK™ cough monitor (Vitalograph Ltd, Buckinghamshire, UK) with cough sounds per hour 
quantified by a semi-automated method using validated custom-written software(12,20,21). 
Cough Challenges: Four breaths of doubling concentrations of capsaicin (0.97-1000µM, Stockport 
Pharmaceuticals Ltd, Stockport, UK) were inhaled at one minute intervals from a dosimeter (Koko® 
dosimeter, De Vilbiss Health Care Inc., Somerset, PA). The number of coughs in the 15 seconds 
following each inhalation was counted The challenge continued until the maximum tolerated dose or 
the final concentration was inhaled(6, 22). The maximum number of coughs evoked at any 
concentration (Emax) was the main endpoint, but the concentration evoking 50% of the maximal 
response (ED50) was also reported. To allow comparison with previous studies the concentration of 
capsaicin evoking two (C2) and five (C5) endpoints were also extracted from the cough challenge data 
for analysis. 
Patient Reported Cough Measures: Subjects rated cough severity and urge-to-cough on separate 
100mm VAS scales for day and night times. Cough specific quality of life was assessed by the Leicester 
Cough Questionnaire (LCQ); higher scores indicated better quality of life(23). 
DATA ANALYSIS 
Vagal depolarisation: Inhibition of depolarisation was analysed utilising a paired t-test, given 
observations were made using the tissue as its own control. Data presented are means ± S.E.M with 
statistical significance set at a value of p<0.05. 
Cough: Inhibition of cough by the TRPV1 antagonists in vivo was analysed initially utilising a Bartlett’s 
Test in order to determine whether the variances were equal and then either a parametric test 
(Analysis of Variance followed by a Bonferroni's Multiple Comparison Test) or a non-parametric test 
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(Kruskal-Wallis followed by Dunn’s Multiple Comparison Test) to compare responses from the 
antagonist group with those from the vehicle control group. Data presented are means ± S.E.M with 
statistical significance set at a value of p<0.05. 
Clinical Study: Sample size was estimated from previous data, (awake cough frequency ~25c/h, log10 
standard deviation 0.23-0.41). Based on these assumptions, 16 patients would be needed to detect a 
56% reduction in awake cough frequency (90% power, 5% significance level). The change from 
baseline in the awake objective cough frequency was analysed with a mixed effects linear model, with 
baseline and treatment period as fixed effects and patient as a random effect. Awake cough 
frequency was log-transformed for analysis and the standard p<0.05 level of significance applied. 
Similar models were applied to the secondary endpoints, with or without log-transformation as 
appropriate. 
 
RESULTS 
PRE-CLINICAL STUDIES 
Guinea-pig and Human Vagus nerve depolarisation 
XEN-D0501 (0.1-100nM) inhibited capsaicin-induced depolarisation of the guinea pig vagus in the 
nanomolar range in a concentration dependent manner with a maximal inhibition of 87.2 ± 4.4% at 
10nM (Figure 2A). The maximally effective concentration of XEN-D0501 (10nM) had no effect on 
responses to the TRPA1 agonist, acrolein (300µM) indicating no off target activity on another TRP 
channel expressed on C-fibre afferents, which when activated is also known to evoke cough in guinea-
pigs and humans(24). SB-705498 (1-10µM) also evoked a concentration dependent inhibition of 
capsaicin-induced depolarisation of guinea pig vagus that was in the micromolar range with a maximal 
inhibition of 52.4 ± 5.5% at 10µM (Figure 2B). Higher concentrations could not be formulated for in 
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vitro experiments as solubility was compromised. Similarly, XEN-D0501 (0.1-100nM) also inhibited 
capsaicin-induced depolarisation of the human vagus in the nanomolar range in a concentration 
dependent manner with 80.54 ± 10.4% at 100nM (Figure 2C). Furthermore, consistent with data 
generated in the guinea-pig, SB-705498 inhibited depolarisation in the micromolar range. 
Capsaicin Evoked Cough in a Conscious Guinea Pig Model 
XEN-D0501 significantly inhibited capsaicin-induced cough at all doses tested (Vehicle: 8.63 ± 2.3 
versus XEN-D0501 (1mg/kg): 2.13 ±0.95 coughs/10min, n=8) (Figure 3A). SB-705498 only significantly 
inhibited cough at the highest dose tested (Vehicle: 6.71 ± 1.9 versus XEN-D0501 (100mg/kg): 0.29 
± 0.29 coughs/10min, n=7) (Figure 3B). XEN-D0501 retained its efficacy following 13 days dosing bd, 
inhibiting capsaicin evoked cough to the same extent as in guinea pigs only receiving a single dose 1 
hour prior to the cough challenge (Figure 3C). 
CLINICAL STUDY 
Subjects 
Twenty patients with refractory chronic cough (mean age 63.1yrs, 15 female) were recruited, see 
Table 1 and Figure 1B. Patients were typical of those attending specialist cough clinics and those 
randomised to each treatment sequence were well matched. Two patients discontinued study 
treatment and withdrew from the study. One patient was withdrawn during XEN-D0501 treatment 
due to a treatment-emergent adverse event of fatigue, considered related to study treatment. A 
further patient was withdrawn during placebo dosing as they did not meet all the inclusion criteria 
and were included in error. A tablet count suggested that compliance with study treatment was high 
and almost identical for XEN-D0501 and placebo. Over the two week treatment periods, this 
Page 11 of 41  AJRCCM Articles in Press. Published on 26-June-2017 as 10.1164/rccm.201704-0769OC 
 Copyright © 2017 by the American Thoracic Society 
12 
 
suggested subjects consumed a mean of 26.7 XEN-D0501 tablets (95%CI 26.5-27.5) and 27.0 (25.9-
27.5) placebo tablets (p=0.56). 
Cough Frequency and Capsaicin Evoked Cough Responses 
Consistent with the pre-clinical data, XEN-D0501 dramatically reduced maximal cough responses to 
capsaicin [Emax mean difference XEN-D0501 -19.3 coughs (±16.4) vs. placebo -1.8 coughs (±5.8), 
p<0.0001], Figure 4. The logC2 and logC5 endpoints also significantly improved from baseline with 
XEN-D0501; increases in logC2 of +1.10µM (SEM ±0.34), p=0.005 and logC5 of +1.22µM (±0.40), 
p=0.007 over placebo, equivalent to increases of +3.7 and +4.1 doubling doses of capsaicin 
respectively. However, there was no difference in the change from baseline in spontaneous daytime 
cough frequency for treatment with XEN-D0501 compared with placebo [awake cough frequency 
(mean change XEN-D0501 6.7c/h (±16.9) vs. placebo 0.4c/h (±13.7), p=0.41), Table 2. Similarly there 
was no significant change in 24h or sleep cough frequency; hourly cough counts on day 14 of 
treatment with placebo and XEN-D0501 are shown in Figure 5. Treatment sequence and period had 
no significant effect in any of these analyses. 
Patient Reported Outcomes 
Overall, the patient reported endpoints did not suggest patients perceived significant improvements 
in their cough. The only exception was awake cough severity VAS which improved with placebo 
treatment compared to XEN-D0501, although the magnitude of the difference was very small indeed 
[mean difference 2.8mm (SD ±21.4), p=0.03]. Again, treatment sequence and period had no 
significant effect in any of the analyses. 
Safety and Adverse Events 
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No serious adverse events (SAEs) were reported during the study. In total, 103 treatment emergent 
adverse events (TEAEs) were reported by 18 (94.7%) patients receiving XEN-D0501; 89 events were 
considered to be treatment-related. Fourteen AEs were reported by 9 (47.4%) patients receiving 
placebo, of which 5 events were considered treatment-related. The most frequently reported AEs 
were related to temperature sensations or mouth related events and were consistent with those seen 
in previous studies(14). The most common AEs, reported by ≥3 patients taking XEN-D0501 were: 
thermohypoaesthesia (n=8), dysgeusia (n=9), and feeling of body temperature change (n=6), feeling 
hot (n=3), oral paraesthesia (n=3), and hyperhidrosis (n=3). Headache was also a frequently reported 
TEAE (n=3 taking XEN-D0501 and n=1 taking placebo). No concerns were raised by other measures of 
safety i.e. ECGs, vital signs including body temperature, physical examination findings, and routine 
haematology and coagulation, clinical chemistry, and urinalysis assessments. 
 
DISCUSSION 
Cough is the most common condition for which patients seek medical attention but currently there 
are no licensed treatments for refractory chronic cough and evidence is lacking to suggest over-the-
counter (OTC) cough medications are effective(25). The cough reflex is regulated by vagal afferent 
nerves which innervate the airway, some are more mechanically sensitive; the Rapidly Adapting 
Receptors (RARs), Slowly Adapting Receptors (SARs), and the subtype known as the ‘cough’ receptor, 
and some are more chemosensitive; C fibres and Aδ nociceptors(7). Ion channels present on these 
vagal nerve termini can be activated by a wide variety of stimuli to elicit cough and other reflexes. The 
main family of ion channels implicated in the initiation of sensory reflexes are TRP channels(7). 
A significant amount of information has been gathered regarding the biology of TRPV1 from clinical, 
capsaicin challenge studies. Interestingly, the threshold for provoking cough by capsaicin (C2 or the C5 
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concentration of capsaicin required to elicit at least 2 or 5 coughs, respectively) has been found to be 
lowered in various populations of patients with Chronic Obstructive Pulmonary(4,26), asthma(22,26), 
Idiopathic Pulmonary Fibrosis(27) and also refractory chronic cough patients(4,5,28) compared to 
healthy controls. These data imply that TRPV1 function is frequently increased in a disease setting. 
However, it is still not certain if increased sensitivity to various challenge agents acting on particular 
ion channels informs us regarding whether a particular intervention will be useful in a certain disease 
setting. In one of the studies above, different patient groups (COPD, healthy smokers, refractory 
chronic cough, and asthma) were compared and exhibited different patterns of modulation of cough 
responses to a range of inhaled irritants. This data supports the concept of disease-specific 
neurophenotypes in airway disease suggesting that chronic cough associated with different 
aetiologies may not be sensitive to similar interventions(4).  
Of all the TRP channels, antagonists for TRPV1 are the most advanced with regard to drug 
development and clinical trials. However, development of these inhibitors has not been 
straightforward due to the activity of TRPV1 as a thermosensor for hot temperatures. This has seen 
several TRPV1 antagonists fail to progress due to adverse effects such as increased body temperature 
and latent withdrawal to noxious hot stimuli. For instance AMG 517 caused significant and long 
lasting increases in body temperature in phase 1 clinical trials in patients following molar extractions. 
In this case the trial was terminated before any efficacy, in relation to possible analgesic effects, could 
be determined(29). Other compounds, also trialled in dental pain studies exhibited similar adverse 
events with increases in body temperature and altered noxious heat sensation. In all cases these 
adverse effects were correlated with target engagement. More recently compounds have been 
identified that are not limited because of adverse events.  
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SB-705498 has been reported to be a potent, selective, orally bioavailable competitive TRPV1 
receptor antagonist which does not exhibit significant disturbances in temperature perception or 
control(30). The availability of safe, “clinical ready” TRPV1 antagonists has already allowed the 
profiling of SB-705498 in a double blind randomised controlled trial in patients with refractory chronic 
cough(12). This trial utilised objective cough monitoring and capsaicin challenge as a 
pharmacodynamic marker of target engagement.  In this study, a single dose of SB-705498 was 
reported to be well tolerated with no significant increase in tympanic temperature or reported 
temperature perception. However, disappointingly SB-705498 lacked efficacy in improving 
spontaneous cough frequency in refractory chronic cough patients, although there was a small but 
statistically significant shift in capsaicin-evoked cough. Pharmacodynamic modelling estimated SB-
705498 receptor occupancy to be 45% at 2 hours (associated with more than a doubling dose shift in 
C5 values over placebo) and 25% at 24 hours (associated with a 0.7 doubling dose shift in C5 values 
over placebo). Therefore, it was not clear whether the lack of efficacy in reducing spontaneous cough 
was due to the modest receptor occupancy and whether a compound with increased potency and 
efficacy at reducing cough to capsaicin would be required. Furthermore, the long half-life of SB-
705498 (50-60hrs) limited previous clinical studies of this drug to investigating the efficacy of single 
doses, and therefore the potential effects of more prolonged TRPV1 blockade could not be 
determined. 
In these experiments we utilised a potent and selective TRPV1 receptor antagonist, XEN-D0501, which 
has been shown to demonstrate sub-nanomolar potency in human recombinant cellular systems and 
rat dorsal root ganglia neuron preparations. In a phase 1 safety study, XEN-D0501 was well tolerated 
with repeat dosing with no serious adverse events and a slight increase in core body temperature 
which attenuated over time and was not considered to be of clinical concern(14). In this study we 
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demonstrate superior efficacy and potency of the TRPV1 antagonist, XEN-D0501, over SB-705498 in a 
range of pre-clinical in vitro and in vivo studies. XEN-D0501 (0.1-10nm) was more efficacious and 
1000-fold more potent than SB705498 (1-10µM) at inhibiting capsaicin-induced depolarisation of 
guinea pig and human isolated vagus. The in vitro potency of SB-705498 in this study was slightly less 
than reported in a FLIPR assay on the guinea-pig and human recombinant TRPV1 receptor expressed 
in HEK293 cells (apparent pKi values of 7.3±0.1 7.6±0.2, respectively). However, one might expect a 
10-fold or more drop off in potency when one looks at the activity against the native ion channel in a 
tissue based assay. In vivo, XEN-D0501 (1mg/kg) completely inhibited capsaicin-induced cough 
whereas 100 times more SB705498 (100mg/kg) was required to achieve the same effect which was 
somewhat consistent with previous data demonstrating some inhibition with SB-705498 (at 10, 
30mg/kg) in a capsaicin induced secondary hyperalgesia model in the rat(31). 
In this study, target engagement was demonstrated in pre-clinical and clinical studies with XEN-D0501 
blocking the cough to capsaicin observed in both models; highlighting the translational capacity of the 
guinea-pig model. Rather than the traditional clinical C5 endpoint which is somewhat arbitrary, we 
utilised novel cough challenge methodology which captures the dose-response relationship between 
capsaicin and cough, using the pharmacodynamic endpoints Emax and ED50(6). We have recently 
shown that Emax better discriminates chronic cough patients from healthy controls and mild asthma 
patients, and it is more readily compared to pre-clinical cough studies. Emax exhibited substantial 
improvements in this study. However, this did not translate into efficacy for XEN-D0501 on 
spontaneous coughing in chronic cough patients.  
This study has some limitations; as a proof of concept study, the sample size was small. Nonetheless 
significant changes in capsaicin cough responses were still clearly demonstrated. Furthermore, both 
our power calculations and previous studies demonstrate that objective cough monitoring is a 
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powerful tool for demonstrating efficacy, and large studies are not required(21). It should also be 
acknowledged that whilst no serious adverse events or changes in body temperature occurred in this 
study, TRPV1 antagonism was still associated with frequent non-severe adverse effects, mainly 
relating to temperature sensing, perceived body temperature and alterations in taste. 
In summary, that potent TRPV1 antagonism, producing considerable reductions in capsaicin evoked 
cough, was not associated with any improvements in objective cough frequency suggests that TRPV1 
is not an effective target in refractory chronic cough. This is in stark contrast to recent demonstrations 
of the efficacy of P2X3 antagonism, implicating this ion channel and its endogenous ligand, ATP, in the 
mechanisms under pinning chronic cough (20). The current study may also provide an indication that 
increased sensitivity to one mechanism (e.g. TRPV1), demonstrated by challenge studies (e.g. utilising 
capsaicin) in one patient group (refractory chronic cough), does not necessarily implicate the utility of 
said target in a particular patient group. However, this may not be the case for TRPV1 in other 
conditions that exhibit chronic cough or with other TRP channels involved in chronic cough. What this 
study does illustrate is that challenge paradigms across pre-clinical and clinical models can deliver 
effective pharmacodynamic models which can inform dosing regimens in future clinical trials across 
any therapeutic area. 
 
ACKNOWLEDGEMENTS 
The authors wish to thank all the subjects who participated in this study, the National Institute of 
Health Research, South Manchester Respiratory & Allergy Clinical Research Facility and Northern 
Ireland Clinical Research Network (Respiratory Health) who supported the clinical study. Pre-clinical 
studies were performed by IR Pharma Ltd, an Imperial College Contract research organisation 
http://www.irpharma.co.uk/. This study was funded by Ario Pharma Ltd and conducted by Xention 
Page 17 of 41  AJRCCM Articles in Press. Published on 26-June-2017 as 10.1164/rccm.201704-0769OC 
 Copyright © 2017 by the American Thoracic Society 
18 
 
Limited who also acted as sponsor. Employees and contractors of the company were involved in the 
design, medical monitoring, trial oversight, trial monitoring, data management, analysis and reporting 
of the study. 
Page 18 of 41 AJRCCM Articles in Press. Published on 26-June-2017 as 10.1164/rccm.201704-0769OC 
 Copyright © 2017 by the American Thoracic Society 
19 
 
REFERENCES 
1. Ford AC, Forman D, Moayyedi P, Morice AH. Cough in the community: a cross sectional survey and 
the relationship to gastrointestinal symptoms. Thorax 2006; 61: 975-979. 
2. Hilton E, Marsden P, Thurston A, Kennedy S, Decalmer S, Smith JA. Clinical features of the urge-to-
cough in patients with chronic cough. Respir Med 2015; 109: 701-707. 
3. McGarvey L, McKeagney P, Polley L, MacMahon J, Costello RW. Are there clinical features of a 
sensitized cough reflex? Pulm Pharmacol Ther 2009; 22: 59-64. 
4. Belvisi MG, Birrell MA, Khalid S, Wortley MA, Dockry R, Coote J, Holt K, Dubuis E, Kelsall A, Maher 
SA, Bonvini S, Woodcock A, Smith JA. Neurophenotypes in Airway Diseases. Insights from 
Translational Cough Studies. Am J Respir Crit Care Med 2016; 193: 1364-1372. 
5. Choudry NB, Fuller RW. Sensitivity of the cough reflex in patients with chronic cough. Eur Respir J 
1992; 5: 296-300. 
6. Hilton EC, Baverel PG, Woodcock A, Van Der Graaf PH, Smith JA. Pharmacodynamic modeling of 
cough responses to capsaicin inhalation calls into question the utility of the C5 end point. J Allergy Clin 
Immunol 2013. 
7. Bonvini SJ, Birrell MA, Smith JA, Belvisi MG. Targeting TRP channels for chronic cough: from bench 
to bedside. Naunyn Schmiedebergs Arch Pharmacol 2015; 388: 401-420. 
8. Caterina MJ, Rosen TA, Tominaga M, Brake AJ, Julius D. A capsaicin-receptor homologue with a high 
threshold for noxious heat. Nature 1999; 398: 436-441. 
9. Grace M, Birrell MA, Dubuis E, Maher SA, Belvisi MG. Transient receptor potential channels 
mediate the tussive response to prostaglandin E2 and bradykinin. Thorax 2012; 67: 891-900. 
10. Belvisi MG, Miura M, Stretton D, Barnes PJ. Capsazepine as a selective antagonist of capsaicin-
induced activation of C-fibres in guinea-pig bronchi. Eur J Pharmacol 1992; 215: 341-344. 
Page 19 of 41  AJRCCM Articles in Press. Published on 26-June-2017 as 10.1164/rccm.201704-0769OC 
 Copyright © 2017 by the American Thoracic Society 
20 
 
11. Forsberg K, Karlsson JA. Cough induced by stimulation of capsaicin-sensitive sensory neurons in 
conscious guinea-pigs. Acta Physiol Scand 1986; 128: 319-320. 
12. Khalid S, Murdoch R, Newlands A, Smart K, Kelsall A, Holt K, Dockry R, Woodcock A, Smith JA. 
Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: 
a double-blind randomized controlled trial. J Allergy Clin Immunol 2014; 134: 56-62. 
13. Lalloo UG, Fox AJ, Belvisi MG, Chung KF, Barnes PJ. Capsazepine inhibits cough induced by 
capsaicin and citric acid but not by hypertonic saline in guinea pigs. J Appl Physiol (1985) 1995; 79: 
1082-1087. 
14. Round P, Priestley A, Robinson J. An investigation of the safety and pharmacokinetics of the novel 
TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol 2011; 72: 921-931. 
15. M.G. Belvisi, M.A. Birrell, M.A. Wortley, S.A. Maher, I. Satia, H. Badri, K. Holt, S. Sen, P. Round, L. 
McGarvey, J. Ford, J.A. Smith. Improved Pharmacodynamic Profile of XEN-D0501, a Novel TRPV1 
Antagonist, Over SB705498 does not Result in a Reduction in Cough Frequency in Patients with 
Chronic Idiopathic Cough [abstract] Am J Respir Crit Care Med 2017; 95: A4499  
16. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research 
reporting: The ARRIVE guidelines for reporting animal research. J Pharmacol Pharmacother 2010; 1: 
94-99. 
17. Bonvini SJ, Birrell MA, Grace MS, Maher SA, Adcock JJ, Wortley MA, Dubuis E, Ching YM, Ford AP, 
Shala F, Miralpeix M, Tarrason G, Smith JA, Belvisi MG. Transient receptor potential cation channel, 
subfamily V, member 4 and airway sensory afferent activation: Role of adenosine triphosphate. J 
Allergy Clin Immunol 2016; 138: 249-261 e212. 
Page 20 of 41 AJRCCM Articles in Press. Published on 26-June-2017 as 10.1164/rccm.201704-0769OC 
 Copyright © 2017 by the American Thoracic Society 
21 
 
18. Birrell MA, Bonvini SJ, Dubuis E, Maher SA, Wortley MA, Grace MS, Raemdonck K, Adcock JJ, 
Belvisi MG. Tiotropium modulates transient receptor potential V1 (TRPV1) in airway sensory nerves: A 
beneficial off-target effect? J Allergy Clin Immunol 2014; 133: 679-687 e679. 
19. Morice AH, McGarvey L, Pavord I, British Thoracic Society Cough Guideline G. Recommendations 
for the management of cough in adults. Thorax 2006; 61 Suppl 1: i1-24. 
20. McGuinness K, Holt K, Dockry R, Smith JA. Validation of the VitaloJAK™ 24 hour ambulatory cough 
monitor [abstract]. Thorax 2012; 67: A131. 
21. Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP, Smith JA. P2X3 receptor 
antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled 
phase 2 study. Lancet 2015; 385: 1198-1205. 
22. Satia I, Tsamandouras N, Holt K, Badri H, Woodhead M, Ogungbenro K, Felton TW, O'Byrne PM, 
Fowler SJ, Smith JA. Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway 
neuronal dysfunction. J Allergy Clin Immunol 2016. 
23. Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific 
health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 
2003; 58: 339-343. 
24. Birrell MA, Belvisi MG, Grace M, Sadofsky L, Faruqi S, Hele DJ, Maher SA, Freund-Michel V, Morice 
AH. TRPA1 agonists evoke coughing in guinea pig and human volunteers. American journal of 
respiratory and critical care medicine 2009; 180: 1042-1047. 
25. Schroeder K, Fahey T. Systematic review of randomised controlled trials of over the counter cough 
medicines for acute cough in adults. BMJ 2002; 324: 329-331. 
26. Doherty MJ, Mister R, Pearson MG, Calverley PM. Capsaicin responsiveness and cough in asthma 
and chronic obstructive pulmonary disease. Thorax 2000; 55: 643-649. 
Page 21 of 41  AJRCCM Articles in Press. Published on 26-June-2017 as 10.1164/rccm.201704-0769OC 
 Copyright © 2017 by the American Thoracic Society 
22 
 
27. Doherty MJ, Mister R, Pearson MG, Calverley PM. Capsaicin induced cough in cryptogenic 
fibrosing alveolitis. Thorax 2000; 55: 1028-1032. 
28. Prudon B, Birring SS, Vara DD, Hall AP, Thompson JP, Pavord ID. Cough and glottic-stop reflex 
sensitivity in health and disease. Chest 2005; 127: 550-557. 
29. Gavva NR, Treanor JJ, Garami A, Fang L, Surapaneni S, Akrami A, Alvarez F, Bak A, Darling M, Gore 
A, Jang GR, Kesslak JP, Ni L, Norman MH, Palluconi G, Rose MJ, Salfi M, Tan E, Romanovsky AA, 
Banfield C, Davar G. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked 
hyperthermia in humans. Pain 2008; 136: 202-210. 
30. Gunthorpe MJ, Hannan SL, Smart D, Jerman JC, Arpino S, Smith GD, Brough S, Wright J, Egerton J, 
Lappin SC, Holland VA, Winborn K, Thompson M, Rami HK, Randall A, Davis JB. Characterization of SB-
705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the 
capsaicin-, acid-, and heat-mediated activation of the receptor. J Pharmacol Exp Ther 2007; 321: 1183-
1192. 
31. Rami HK, Thompson M, Stemp G, Fell S, Jerman JC, Stevens AJ, Smart D, Sargent B, Sanderson D, 
Randall AD, Gunthorpe MJ, Davis JB. Discovery of SB-705498: a potent, selective and orally 
bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett 2006; 16: 
3287-3291.
Page 22 of 41 AJRCCM Articles in Press. Published on 26-June-2017 as 10.1164/rccm.201704-0769OC 
 Copyright © 2017 by the American Thoracic Society 
23 
 
TABLES 
Table 1. Characteristics of randomised participants. Data are mean and standard deviations. 
 
Treatment Sequence 
Overall XEN-D0501/ 
Placebo 
(n=11) 
Placebo/ XEN-
D0501 
(n=9) 
Age  (years) 64.9 (7.8) 60.8 (11.0) 63.1 (9.4) 
Sex 
Male 
(n, %)  
3 (27.3%) 2 (22.2%) 5 (25.0%) 
Female  
(n, %)  
8 (72.7%) 7 (77.8%) 15 (75.0%) 
Race (n, %) White  11 (100.0%) 9 (100.0%) 20 (100.0%) 
Height (cm)  161.9 (6.8) 164.1 (8.4) 162.9 (7.4) 
Weight (kg)  77.0 (15.5) 71.7 (17.9) 74.6 (16.4) 
BMI (kg/m2)  29.3 (4.9) 26.3 (4.8) 28.0 (5.0) 
FEV1 % predicted 105.5% (13.1) 104.8% (15.6) 105.2% (13.9) 
Former smoker  3 (27.3) 1 (11.1) 4 (20.0) 
Never smoked  8 (72.7) 8 (88.9) 16 (80.0) 
Current smoker  0 0 0 
Pack years (ex-smokers) 4.7 (4.0) 4.0 4.5 (3.3) 
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Table 2. Measures of Cough at baseline and after 2 weeks treatment with XEN-0501 and matched 
placebo. Data are means and standard deviations unless otherwise stated. 
 
XEN-D0501 
(n=18) 
Placebo 
(n=19) 
p 
Baseline Day 14 Baseline Day 14  
Objective 
Cough 
Frequency 
Awake 
34.4c/h 
(±41.9) 
41.1c/h 
(±52.7) 
40.9c/h 
(±63.2) 
41.3c/h 
(±58.3) 
0.42 
24h 
24.2c/h 
(±29.0) 
29.5c/h 
(±36.8) 
29.2c/h 
(±46.0) 
30.5c/h 
(±44.0) 
0.43 
Night 
median 
(IQR) 
0.7c/h 
(0.3-2.3) 
1.7c/h 
(0.8-4.5) 
2.3c /h 
(0.9-3.3) 
1.4c/h 
(0.7-4.4) 
0.29 
Cough 
Severity 
VAS 
Day 
40.6mm 
(±26.6mm)  
39.7mm 
(±32.5mm)  
34.3mm 
(±23.0mm)  
31.5mm 
(±27.8mm)  
0.03 
Night 
21.9mm 
(±25.8mm)  
16.4mm 
(±22.3mm)  
20.2mm 
(±17.5mm)  
14.7mm 
(±18.2mm)  
0.12 
Urge to 
Cough 
VAS 
Day 
42.9mm 
(±26.2mm)  
34.6mm 
(±30.9mm)  
31.1mm 
(±21.5mm)  
27.2mm 
(±25.3mm)  
0.25 
Night 
22.2mm 
(±23.8mm)  
16.3mm 
(±24.3mm)  
18.4mm 
(±17.0mm)  
14.6mm 
(±22.5mm)  
0.58 
Cough Quality of Life 
(LCQ) 
13.05 
(4.09) 
13.80 
(4.03) 
13.70 
(4.53) 
14.43 
(4.43) 
0.82 
Capsaicin 
Challenge 
Emax 
32.3 coughs 
(±17.1)  
13.1 coughs 
(±11.3) 
27.7 coughs 
(±15.2) 
25.9 coughs 
(±12.3) 
<0.001 
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FIGURE LEGENDS: 
Figure 1. Clinical Study Design and Consort Diagram. 
(A) Summary of the double blind randomised crossover design of the clinical study including timing of 
efficacy and pharmacodynamics endpoints. (B) Patient recruitment and flow; one patient withdrew* 
after 5 days treatment with XEN-0501 due to intolerance to the study drug and a second patient was 
withdrawn† during placebo dosing as they were included in the study in error. 
Figure 2. Inhibition of Vagal Sensory Nerve activation. 
The effect of vehicle (0.1% DMSO v/v) or (A) XEN-D0501 (0.1-100nM.) or (B) SB705498 (1-10 µM) on 
depolarization of the guinea-pig vagus induced by capsaicin (1µM). A similar effect was produced in 
human vagus (C); typical example traces (D). Data expressed as mean ± S.E.M, n=4 and n=3 
observations per treatment group in guinea-pig and human studies, respectively. 
Figure 3. Inhibition of Capsaicin-induced Cough in a Conscious Guinea-pig model 
The effect of vehicle (0.5% methylcellulose, 0.1% Tween80, 5ml/kg, i.p.) or (A) XEN-D0501 (1, 3 or 10 
mg/kg, i.p., n=8) or (B) SB705498 (10, 30 or 100 mg/kg, i.p., n=7) administered 1 hour prior to cough 
recording on capsaicin (60 µM in 1% ethanol, 1% Tween 80 in 0.9% sterile saline for 5 mins, coughs 
counted for 10mins) -induced cough in a conscious guinea-pig model. (C) In repeat dose studies 
capsaicin-induced cough was assessed after acute and chronic dosing of XEN-D0501 (1 or 3 mg/kg, 
i.p., bd, n=8) or vehicle. Data expressed as mean ± S.E.M. Inhibition of cough by the TRPV1 
antagonists in vivo was analysed initially utilising a Bartlett’s Test in order to determine whether the 
variances were equal and then either a parametric test (Analysis of Variance followed by a 
Bonferroni's Multiple Comparison Test-data set in A) or a non-parametric test (Kruskal-Wallis followed 
by Dunn’s Multiple Comparison Test-data sets B & C) to compare responses from the antagonist 
Page 25 of 41  AJRCCM Articles in Press. Published on 26-June-2017 as 10.1164/rccm.201704-0769OC 
 Copyright © 2017 by the American Thoracic Society 
26 
 
group with those from the vehicle control group. Data presented are means ± S.E.M with statistical 
significance set at a value of P < 0.05. 
Figure 4. Capsaicin Evoked Cough Responses. 
Individual patient maximal cough responses to capsaicin (Emax), at baseline and after 2 weeks of 
treatment with placebo and XEN-D0501. XEN-D0501 significantly reduced Emax compared with 
placebo, p<0.001. 
Figure 5. Hourly Cough Frequency. 
Comparison of cough frequency hour by hour on day 14 of treatment with XEN-0501 compared with 
placebo; data shown are medians. 
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Figure 1. Clinical Study Design and Consort Diagram. (A) Summary of the double blind randomised 
crossover design of the clinical study including timing of efficacy and pharmacodynamics endpoints. (B) 
Patient recruitment and flow; one patient withdrew* after 5 days treatment with XEN-0501 due to 
intolerance to the study drug and a second patient was withdrawn† during placebo dosing as they were 
included in the study in error.  
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Figure 2. The effect of vehicle (0.1% DMSO v/v) or (A) XEN-D0501 (0.1-100nM.) or (B) SB705498 (1-10µM) 
on depolarization of the guinea-pig vagus induced by capsaicin (1µM). A similar effect was produced in 
human vagus (C); typical example traces (D). Data expressed as mean +/-S.E.M, n=4 and n=3 
observations per treatment group in guinea-pig and human studies, respectively.  
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Figure 3. Inhibition of Capsaicin-induced Cough in a Conscious Guinea-pig model. The effect of vehicle 
(0.5% methylcellulose, 0.1% Tween80, 5ml/kg, i.p.) or (A) XEN-D0501 (1, 3 or 10 mg/kg, i.p., n=8) or (B) 
SB705498 (10, 30 or 100 mg/kg, i.p., n=7) administered 1 hour prior to cough recording on capsaicin 
(60µM in 1% ethanol, 1% Tween 80 in 0.9% sterile saline for 5 mins, coughs counted for 10mins) -induced 
cough in a conscious guinea-pig model. (C) In repeat dose studies capsaicin-induced cough was assessed 
after acute and chronic dosing of XEN-D0501 (1 or 3 mg/kg, i.p., bd, n=8) or vehicle. Data expressed as 
mean +/-S.E.M. Inhibition of cough by the TRPV1 antagonists in vivo was analysed initially utilising a 
Bartlett’s Test in order to determine whether the variances were equal and then either a parametric test 
(Analysis of Variance followed by a Bonferroni's Multiple Comparison Test-data set in A) or a non-parametric 
test (Kruskal-Wallis followed by Dunn’s Multiple Comparison Test-data sets B & C) to compare responses 
from the antagonist group with those from the vehicle control group. Data presented are means +/-S.E.M 
with statistical significance set at a value of p<0.05.  
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Figure 4. Capsaicin Evoked Cough Responses. Individual patient maximal cough responses to capsaicin 
(Emax), at baseline and after 2 weeks of treatment with placebo and XEN-D0501. XEN-D0501 significantly 
reduced Emax compared with placebo, p<0.001.  
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Figure 5. Hourly Cough Frequency. Comparison of cough frequency hour by hour on day 14 of treatment 
with XEN-0501 compared with placebo; data shown are medians.  
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SUPPLEMENTARY METHODS 
PRE-CLINICAL STUDIES 
Animals 
In vivo and ex vivo experiments were conducted in male Dunkin-Hartley guinea pigs (300-500g) 
(Harlan and B&K Universal, UK) housed in a temperature controlled (21°C) room with food and 
water freely available for at least one week before commencing the experimentation. The 
experiments were performed in accordance with the UK Home Office guidelines for animal 
welfare based on the Animals (Scientific Procedures) act 1986 and the ARRIVE guidelines
15
. 
Guinea-pig and human isolated vagus nerve recording 
Recording of depolarisation (as a measure of vagal, afferent sensory nerve activity) of isolated 
guinea-pig and human vagus was carried out as described previously
9,16,17
. Briefly, nerves were 
stimulated twice with capsaicin (1µM) for 2min before vehicle or XEN-D0501 (0.1-100nM) or SB-
705498 (1-10µM) was perfused for 10min. Response to capsaicin (1µM) was then re-assessed in 
presence of vehicle or test compounds. After a 10min washout, nerves were finally stimulated 
again with capsaicin (1µM) to confirm viability. One concentration of the antagonist was tested 
per vagus preparation. 
Human en bloc lungs unsuitable for transplantation were obtained from International Institute for 
the Advancement of Medicine (New Jersey, USA), and vagal tissue was obtained (N = 4, 36-57 
years old, 3 male).  In all cases tissue was consented for use in scientific research. Ethics approval 
was obtained from the Royal Brompton & Harefield Trust. 
Capsaicin evoked cough in guinea-pigs 
Vehicle (0·5% methylcellulose, 0·1% Tween80, 5ml/kg, i.p.) or XEN-D0501 (1-10mg/kg, i.p.) or SB-
705498 (10-100mg/kg, i.p.) were administered 1 hour prior to cough recording. In all experiments 
the operator was blinded to the treatment groups and the dosing was performed by an 
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independent operator. Conscious, unrestrained guinea-pigs were placed in individual plastic 
transparent whole-body plethysmograph chambers (Buxco, Wilmington, NC, USA) and cough 
assessed to an aerosol of capsaicin (60µM in 1% ethanol, 1% Tween 80 in 0.9% sterile saline for 
5mins) and coughs counted for 10mins as previously described
9,17
. Studies were also performed to 
establish if the XEN-D0501 compound retained efficacy after repeat dosing. In these studies 
guinea-pigs were dosed with vehicle (0·5% methylcellulose, 0·1% Tween80, 5ml/kg, i.p.) or 
compound (1 or 3mg/kg, bd) for 13 days and then 1 hour prior to cough assessment. Capsaicin-
induced cough was then assessed as previously. 
CLINICAL STUDY 
Study Design 
A double-blind, randomised, placebo-controlled, crossover study was performed to evaluate the 
anti-tussive efficacy of 14 days treatment with XEN-D0501 (oral 4mg bd) compared with matched 
placebo; the two treatment periods were separated by a 14 day washout, see Figure 1A. 
Participants were recruited from two specialist cough clinics (University Hospital of South 
Manchester, Manchester and Belfast City Hospital, Belfast) between July 2014 and June 2015. 
Cough was assessed prior to dosing and at the end of each treatment period using an ambulatory 
cough monitor and patient reported outcomes included cough severity rated on a visual analogue 
scale (VAS), cough specific quality of life and a global rating of change scale. Capsaicin evoked 
cough responses were included as a pharmacodynamic endpoint. 
Participants 
We recruited subjects with refractory chronic cough, as determined by national cough guidelines 
(BTS Thorax 2006
18
). An awake cough frequency of >1·5c/h and a maximal capsaicin cough 
response over 4 inhalations (Emax) of >10 coughs were required for inclusion, to remove patients 
with very low cough frequency and capsaicin evoked cough responses, where a treatment effect 
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would be difficult to demonstrate. The study was approved by an independent Research Ethics 
Committee (NRES Committee North West - Liverpool East Ref: 14/NW/0211) and all patients gave 
written informed consent. 
Inclusion Criteria 
To participate in this study, patients were required to meet all of the following criteria: 
1. Male and female patients aged 18 years or over with chronic idiopathic cough, defined as: 
• Attending a specialist cough clinic with a history of cough for more than 8 weeks 
• Idiopathic cough (defined as a cough for which no objective evidence of an underlying 
trigger could be determined after investigation) or treatment-resistant cough (defined as a 
cough that was unresponsive to 8 weeks of targeted treatment for identified underlying 
triggers including reflux disease, asthma and post-nasal drip). 
2. Normal (no clinically relevant findings in the opinion of the investigator) chest radiography ie, 
chest X-ray or CT thorax, prior to the study (within 12 months of Visit 1). 
3. Normal spirometry (ie, forced expiratory volume in 1 second [FEV1] >80% predicted). 
4. Day time cough frequency >1.5 coughs/hour (from 24-hour cough monitor at Visit 2). 
5. Emax (maximum number of coughs following capsaicin challenge) from capsaicin challenge >10 
coughs (from challenge cough monitor at Visit 2). 
6. Women must be of non-child bearing potential: 
• Non-child bearing potential was defined as amenorrhoeic for at least 1 year AND, if aged 
under 60 years, have FSH level of at least 30 IU/L or have undergone a hysterectomy or 
bilateral oophorectomy (tubal ligation was not acceptable). Women who were taking 
hormone replacement therapy (HRT) did not have to have FSH assessments, but the 
amenorrhea (before starting HRT) must have been naturally (spontaneously) occurring and 
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have been accompanied by an appropriate clinical profile (eg, age appropriate, history of 
vasomotor symptoms) 
• If female partners of male patients were of childbearing potential, the patient must have 
been willing to use contraception (eg, condoms plus spermicide) AND their female partner 
must also have been using contraception (eg, hormonal or intra-uterine device). This 
double contraception must have been used from the first dose of study drug until at least 
90 days after the last dose of study drug. 
7. Written informed consent. 
Exclusion Criteria 
Patients meeting any of the following were excluded from participation in the study. Where 
criteria were time-dependent, patients may have been re-screened to enable inclusion: 
1. Body Mass Index (BMI) >35 kg/m2. 
2. Current smokers or patients with urine cotinine ≥500 ng/mL. 
3. Ex-smoker of <6 months. 
4. Cumulative smoking history of ≥10 pack years. 
5. Upper respiratory tract infection within the last 6 weeks prior to randomisation (Visit 3). 
6. Feverish illness within the last 1 week prior to randomisation (Visit 3). 
7. Concomitant medications which may have influenced cough or interact with study drugs eg, 
opioids, gabapentin, pregabalin, amitriptyline, ACE inhibitors, potent CYP3A4 inhibitors (such as 
ketoconazole, clarithromycin or human immunodeficiency virus [HIV] protease inhibitors) and 
systemic corticosteroids (use of local injectable, topical or inhaled corticosteroids was permitted). 
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8. Patients with concomitant conditions which may have influenced the cough reflex or the 
patient's ability to participate in the study eg, diabetes, cerebrovascular disease, Parkinson's 
disease. 
9. History of drug or alcohol dependency or abuse within approximately the last year prior to 
screening (Visit 1). 
10. Regular alcohol consumption; >21 units/week for males, or >14 units/week for females, during 
the study (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine). 
11. Any known allergy to the study drugs. 
12. Pregnant and/or lactating women. 
13. History or evidence of urinary retention, bladder outlet obstruction or benign prostatic 
hypertrophy. 
14. Any clinically significant abnormalities in haematology or clinical biochemistry tests prior to 
randomisation (Visit 3). 
15. Serum alanine transaminase (ALT), aspartate transaminase (AST) or gamma-glutamyl 
transpeptidase (GGT) greater than twice the upper limit of normal (ULN) at Visit 1. 
16. Total serum bilirubin >1.5x ULN at Visits 1. 
17. History of any kind of cancer within the last 5 years unless non-invasive, in remission and 
approved in writing by Sponsor. 
18. Evidence of any other clinically significant disease or condition which in the opinion of the 
investigator would have precluded the patient's participation in this study. 
19. QT interval corrected for heart rate using Fredericia’s formula (QTcF) value at Visit 1 (mean) of 
>450 msec (males) or >470 msec (females). 
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20. Patients with uncontrolled hypertension, systolic blood pressure >160 mmHg or diastolic blood 
pressure >90 mmHg at Visit 1 (mean) or Visit 2. 
21. Received investigational or marketed products as part of any other clinical study within 30 
days (or 5 half-lives whichever was longer) prior to screening (Visit 1). 
22. Patient was unable or unwilling to co-operate with the study procedures. 
Randomisation and Masking 
Patients were assigned to one of the two possible treatment sequences by a computer-generated 
randomisation schedule with a ratio of 1:1 for XEN-D0501/placebo or placebo/XEN-D0501. Blinded 
study drug supplies were provided to each site in sequentially numbered identical bottles in 
accordance with the randomisation schedule, and dispensed by the local hospital pharmacies. 
Patients, health-care providers, investigators and the sponsor were all masked to the treatment 
sequence assignment. A sealed code-break envelope for each patient containing details of the 
treatment allocated was kept in a locked safe at the study site. 
Procedures 
All subjects were assessed at four time points; for both treatment periods this was prior to dosing 
(24hr cough recording day 0, followed by capsaicin challenge day 1) and at the end of the 
treatment period (24hr cough recording day 13, followed by capsaicin challenge on day 14 after 
the final dose of medication), see Figure 1A. Patient demographics, treatments and co-morbidities 
were collected at screening. Randomised subjects underwent two treatment periods of 14 days 
duration, separated by a 14 day washout; a final follow-up evaluation was performed at 7-14 days 
after the final dose. Safety was assessed through monitoring of vital signs, ECGs, body 
temperature, haematology, biochemistry and adverse events. Concomitant medications were 
monitored throughout the study. 
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Outcomes 
The primary endpoint was awake objective cough frequency collected using a 24h ambulatory 
cough monitor commenced at day 0 and day 13 of each treatment period; sleep and 24h cough 
frequency were also determined. The secondary endpoints included changes from baseline in a 
100mm cough severity (VAS), cough specific quality of life assessed by the Leicester Cough 
Questionnaire (LCQ) and also a 15-point global rating of change scales for both cough severity and 
cough frequency (seven ratings for improvement, seven ratings for worsening and one rating for 
unchanged), completed at the end of each treatment period. Cough responses to inhaled capsaicin 
provided a pharmacodynamic endpoint and were assessed on day 1 and 14, following completion 
of each 24h cough recording. 
Ambulatory Cough Monitoring: Twenty-four hour acoustic recordings were made using the 
VitaloJAK™ cough monitor (Vitalograph Ltd, Buckinghamshire, UK) and the number of cough 
sounds per hour quantified by a semi-automated method using validated custom-written 
software
12,19,20
. 
Cough Challenges: Four breaths of doubling concentrations of capsaicin (0·97-1000µM, Stockport 
Pharmaceuticals Ltd, Stockport, UK) were inhaled at one minute intervals from a nebuliser pot (De 
Vilbiss Health Care Inc., Somerset, PA) with a built in flow regulator valve and fixed baffle 
assembly, controlled by a dosimeter (Koko® dosimeter, De Vilbiss Health Care Inc., Somerset, PA). 
The number of coughs in the 15 seconds following each inhalation was counted and recorded by 
the VitaloJAK. The challenge continued until the maximum tolerated dose or the final 
concentration was inhaled
6,21
. The maximum number of coughs evoked at any concentration (Emax) 
was the main endpoint, but the concentration evoking 50% of the maximal response (ED50) was 
also reported. 
To explore how these novel endpoints compare with traditional cough challenge endpoints, we 
also calculated the concentration of capsaicin evoking atleast 2 and 5 coughs, i.e. the C2 and C5. 
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Our challenge protocol is slightly different from the traditional challenge as four inhalations are 
performed at each concentration, rather than just one. Therefore, to calculate the C2 and C5 we 
simply used the number coughs evoked by the first of these four inhalations. If subjects did not 
cough 2 or 5 times during the whole challenge then for the purposes of analysis a value of 
2000µmol/L was assigned. If patients coughed 2 or 5 times on inhalation of placebo then the data 
was considered missing. 
Patient Reported Cough Measures: Subjects rated cough severity and urge-to-cough on separate 
100mm VAS scales for day and night times. Cough specific quality of life was assessed by the LCQ; 
higher scores indicated better quality of life
22
. 
DATA ANALYSIS 
Vagal depolarisation: Inhibition of depolarisation was analysed utilising a paired t-test, given 
observations were made using the tissue as its own control. Data presented are means ± S.E.M 
with statistical significance set at a value of p<0·05. 
Cough: Inhibition of cough by the TRPV1 antagonists in vivo was analysed initially utilising a 
Bartlett’s Test in order to determine whether the variances were equal and then either a 
parametric test (Analysis of Variance followed by a Bonferroni's Multiple Comparison Test) or a 
non-parametric test (Kruskal-Wallis followed by Dunn’s Multiple Comparison Test) to compare 
responses from the antagonist group with those from the vehicle control group. Data presented 
are means ± S.E.M with statistical significance set at a value of p<0·05. 
Clinical Study: Sample size was estimated from previous data, where awake cough frequency in 
chronic cough was ~25c/h, with a log10 standard deviation of 0·23 to 0·41. Based on these 
assumptions, to detect a 56% reduction in awake cough frequency, 16 patients would be needed 
to achieve 90% power with a 5% significance level. The change from baseline in the awake 
objective cough frequency was analysed with a mixed effects linear model, with baseline and 
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treatment period as fixed effects and patient as a random effect. The awake cough frequency was 
log-transformed for analysis and the standard p<0·05 level of significance applied. Similar models 
were applied to the secondary endpoints, with or without log-transformation as appropriate. 
Role of the Funding Source 
This study was funded by Ario Pharma Ltd, and conducted by Xention Ltd who also acted as the 
study sponsor. Employees and contractors of the company were involved in the design, medical 
monitoring, trial oversight, trial monitoring, data management, analysis and reporting of the 
study. 
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